These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30393817)

  • 1. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
    Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
    Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
    Ashida A; Sakaizawa K; Uhara H; Okuyama R
    Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
    Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy.
    Chan WY; Lee JH; Stewart A; Diefenbach RJ; Gonzalez M; Menzies AM; Blank C; Scolyer RA; Long GV; Rizos H
    J Exp Clin Cancer Res; 2024 Aug; 43(1):238. PubMed ID: 39169411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
    Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
    JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
    Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
    Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
    Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
    Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
    Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
    Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
    Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
    J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of metastases using circulating tumour DNA in uveal melanoma.
    Beasley AB; de Bruyn DP; Calapre L; Al-Ogaili Z; Isaacs TW; Bentel J; Reid AL; Dwarkasing RS; Pereira MR; Khattak MA; Meniawy TM; Millward M; Brosens E; de Klein A; Chen FK; Kiliҫ E; Gray ES
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14953-14963. PubMed ID: 37608028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
    Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
    Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
    Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
    Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.
    Lee RJ; Gremel G; Marshall A; Myers KA; Fisher N; Dunn JA; Dhomen N; Corrie PG; Middleton MR; Lorigan P; Marais R
    Ann Oncol; 2018 Feb; 29(2):490-496. PubMed ID: 29112704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring Melanoma Using Circulating Free DNA.
    Diefenbach RJ; Lee JH; Rizos H
    Am J Clin Dermatol; 2019 Feb; 20(1):1-12. PubMed ID: 30374893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma.
    Ashida A; Sakaizawa K; Mikoshiba A; Kiniwa Y; Okuyama R
    Acta Derm Venereol; 2019 Nov; 99(12):1184-1185. PubMed ID: 31396634
    [No Abstract]   [Full Text] [Related]  

  • 16. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.
    Forthun RB; Hovland R; Schuster C; Puntervoll H; Brodal HP; Namløs HM; Aasheim LB; Meza-Zepeda LA; Gjertsen BT; Knappskog S; Straume O
    Sci Rep; 2019 Nov; 9(1):17471. PubMed ID: 31767937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.
    Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
    Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
    J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.
    Emelyanova MA; Telysheva EN; Orlova KV; Ryabaya OO; Snigiryova GP; Abramov IS; Mikhailovich VM
    Cancer Genet; 2021 Jan; 250-251():25-35. PubMed ID: 33249369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
    Marsavela G; McEvoy AC; Pereira MR; Reid AL; Al-Ogaili Z; Warburton L; Khattak MA; Abed A; Meniawy TM; Millward M; Ziman MR; Calapre L; Gray ES
    Br J Cancer; 2022 Feb; 126(3):401-408. PubMed ID: 34373567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.